Literature DB >> 26663424

Cost-Effectiveness of a Chronic Care Model for Frail Older Adults in Primary Care: Economic Evaluation Alongside a Stepped-Wedge Cluster-Randomized Trial.

Karen M van Leeuwen1,2, Judith E Bosmans2, Aaltje P D Jansen1, Emiel O Hoogendijk1,3, Maaike E Muntinga1,4, Hein P J van Hout1, Giel Nijpels1, Henriette E van der Horst1, Maurits W van Tulder2.   

Abstract

OBJECTIVES: To evaluate the cost-effectiveness of the Geriatric Care Model (GCM), an integrated care model for frail older adults based on the Chronic Care Model, with that of usual care.
DESIGN: Economic evaluation alongside a 24-month stepped-wedge cluster-randomized controlled trial.
SETTING: Primary care (35 practices) in two regions in the Netherlands. PARTICIPANTS: Community-dwelling older adults who were frail according to their primary care physicians and the Program on Research for Integrating Services for the Maintenance of Autonomy case-finding tool questionnaire (N = 1,147). INTERVENTION: The GCM consisted of the following components: a regularly scheduled in-home comprehensive geriatric assessment by a practice nurse followed by a customized care plan, management and training of practice nurses by a geriatric expert team, and coordination of care through community network meetings and multidisciplinary team consultations of individuals with complex care needs. MEASUREMENTS: Outcomes were measured every 6 months and included costs from a societal perspective, health-related quality of life (Medical Outcomes Study 12-item Short-Form Survey (SF-12) physical (PCS) and mental component summary (MCS) scales), functional limitations (Katz activities of daily living and instrumental activities of daily living), and quality-adjusted life years based on the EQ-5D.
RESULTS: Multilevel regression models adjusted for time and baseline confounders showed no significant differences in costs ($356, 95% confidence interval = -$488-1,134) and outcomes between intervention and usual care phases. Cost-effectiveness acceptability curves showed that, for the SF-12 PCS and MCS, the probability of the intervention being cost-effective was 0.76 if decision-makers are willing to pay $30,000 per point improvement on the SF-12 scales (range 0-100). For all other outcomes the probability of the intervention being cost-effective was low.
CONCLUSION: Because the GCM was not cost-effective compared to usual care after 24 months of follow-up, widespread implementation in its current form is not recommended.
© 2015, Copyright the Authors Journal compilation © 2015, The American Geriatrics Society.

Entities:  

Keywords:  economic evaluation; frail older adults; integrated care; primary care; stepped-wedge randomized controlled trial

Year:  2015        PMID: 26663424     DOI: 10.1111/jgs.13834

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  22 in total

1.  The state of social care: the reality of a fragmented system.

Authors:  Theresa Eynon; Simon Conroy
Journal:  Br J Gen Pract       Date:  2017-05       Impact factor: 5.386

2.  Health Economic Evaluation Alongside Stepped Wedge Trials: A Methodological Systematic Review.

Authors:  Thomas Lung; Lei Si; Richard Hooper; Gian Luca Di Tanna
Journal:  Pharmacoeconomics       Date:  2020-10-05       Impact factor: 4.981

3.  Integrated and Person-Centered Care for Community-Living Older Adults: A Cost-Effectiveness Study.

Authors:  Ronald J Uittenbroek; Antoinette D I van Asselt; Sophie L W Spoorenberg; Hubertus P H Kremer; Klaske Wynia; Sijmen A Reijneveld
Journal:  Health Serv Res       Date:  2018-03-24       Impact factor: 3.402

Review 4.  Comprehensive Geriatric Assessment for community-dwelling, high-risk, frail, older people.

Authors:  Robert Briggs; Anna McDonough; Graham Ellis; Kathleen Bennett; Desmond O'Neill; David Robinson
Journal:  Cochrane Database Syst Rev       Date:  2022-05-06

5.  International depiction of the cost of functional independence limitations among older adults living in the community: a systematic review and cost-of-impairment study.

Authors:  Ryan S Falck; Alexis G Percival; Daria Tai; Jennifer C Davis
Journal:  BMC Geriatr       Date:  2022-10-22       Impact factor: 4.070

6.  Cost-effectiveness of nurse-led multifactorial care to prevent or postpone new disabilities in community-living older people: Results of a cluster randomized trial.

Authors:  Jacqueline J Suijker; Janet L MacNeil-Vroomen; Marjon van Rijn; Bianca M Buurman; Sophia E de Rooij; Eric P Moll van Charante; Judith E Bosmans
Journal:  PLoS One       Date:  2017-04-17       Impact factor: 3.240

7.  Implementation of integrated geriatric care at a German hospital: a case study to understand when and why beneficial outcomes can be achieved.

Authors:  Loraine Busetto; Jörn Kiselev; Katrien Ger Luijkx; Elisabeth Steinhagen-Thiessen; Hubertus Johannes Maria Vrijhoef
Journal:  BMC Health Serv Res       Date:  2017-03-07       Impact factor: 2.655

8.  Evaluation design of Urban Health Centres Europe (UHCE): preventive integrated health and social care for community-dwelling older persons in five European cities.

Authors:  Carmen B Franse; Antonius J J Voorham; Rob van Staveren; Elin Koppelaar; Rens Martijn; Elisa Valía-Cotanda; Tamara Alhambra-Borrás; Tasos Rentoumis; Lovorka Bilajac; Vanja Vasiljev Marchesi; Tomislav Rukavina; Arpana Verma; Greg Williams; Gary Clough; Jorge Garcés-Ferrer; Francesco Mattace Raso; Hein Raat
Journal:  BMC Geriatr       Date:  2017-09-11       Impact factor: 3.921

9.  Cost-effectiveness of a multicomponent primary care program targeting frail elderly people.

Authors:  Franca G H Ruikes; Eddy M Adang; Willem J J Assendelft; Henk J Schers; Raymond T C M Koopmans; Sytse U Zuidema
Journal:  BMC Fam Pract       Date:  2018-05-16       Impact factor: 2.497

10.  Paradoxes of person-centred care: A discussion paper.

Authors:  Martina Summer Meranius; Inger K Holmström; Jakob Håkansson; Agneta Breitholtz; Farah Moniri; Sofia Skogevall; Karin Skoglund; Dara Rasoal
Journal:  Nurs Open       Date:  2020-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.